News
The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.
The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.
Arrowhead Pharma Kicks Off Phase III Trial for Zodasiran in Homozygous Familial Hypercholesterolemia
The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.
Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.
Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...
The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.
The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.
After Decades Without Progress in Glioblastoma, Diakonos Stirs Up Interest in Dendritic Cell Vaccine
The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.
The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.
The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results